Skip to main content
menu toggle button
What we do
Main menu
Capabilities
Capabilities
Our Integrated Model
Commercialization
3PL and Importation
Regulatory services
Consulting services
Patient support programs
Clinics and nursing
Pharmacovigilance
Specialty Distribution
Pharmacy
Solutions
Solutions
Corporate Wellness programs
Digital Health Solutions
Innomar Pharmacy
Innomar Clinics
Who we are
Main menu
About us
Our leadership team
Corporate citizenship
INSIGHTS
NEWS & EVENTS
CAREERS
Find a clinic
Contact us
language picker toggle button
English
English
Français
search toggle button
Find a clinic
Contact us
INSIGHTS
NEWS & EVENTS
CAREERS
language picker toggle button
English
English
Français
Insights
Filter By
All Topics
Affordability
Analytics
Biosimilars
Commercialization
COVID-19
Data
Digital Solutions
Distribution
Legislation
Market access
Medical Device
Medication adherence
Medication therapy management
Oncology
Our role in healthcare
Patient care
Patient support services
Policy
Product access
Regulatory
Reimbursement
Research
Specialty pharmacy
Technology
Third-party logistics
Sort By
Date (Newest to Oldest)
Date (Oldest to Newest)
Title (A-Z)
Title (Z-A)
Filter
Innomar Strategies
QA consultants: Easing entry into the Canadian market
Innomar Strategies
February 2025
Manufacturers
Market access: Navigating the Canadian reimbursement landscape
Innomar Strategies
October 2024
Manufacturers
Drug advertisement in Canada: What you need to know
Innomar Strategies
September 2024
Manufacturers
Regulatory compliance: Navigating the Canadian landscape for specialty products
Innomar Strategies
September 2024
Manufacturers
Patient support programs: A significant source of real-world data
Innomar Strategies
July 2024
Manufacturers
Real world evidence: The importance for rare disease therapies
Innomar Strategies
July 2024
Manufacturers
Innomar Strategies: Comprehensive 3PL and QA services
Innomar Strategies
July 2024
Manufacturers
QA and 3PL licences: Helping you stay compliant
Innomar Strategies
July 2024
Explore More by Topic
Affordability
Analytics
Biosimilars
Commercialization
COVID-19
Data
brand="Cencora" culture="EN" env="Production" tracker="False"
